Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies

Unlocking the potential of approved drugs for the allosteric inhibition of tropomyosin-receptor kinase A using molecular docking and molecular dynamics studies

Tropomyosin-receptor kinase A (TrkA) is the primary isoform among the tropomyosin-receptor kinases that have been associated with human cancer development, contributing to approximately 7.4% of all cancer cases. TrkA represents an attractive target for cancer treatment; however, currently available...

Full description

Bibliographic Details
Main Authors: Rua M. Mukhtar, Nihal Abdelmoniem, Hisham A. Elrufaie, Alaa Edris, Hiba Ghaboosh, Mohanad A. Mahgoub, Elrashied A. E. Garelnabi, Wadah Osman, Asmaa E. Sherif, Ahmed Ashour, Kholoud F. Ghazawi, Waad A. Samman, Aisha A. Alhaddad, Rawan Bafail, Sabrin R. M. Ibrahim, Gamal A. Mohamed, Abdulrahim A. Alzain
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Chemistry
Subjects:
cancer
tropomyosin-receptor kinase A
repurposing
molecular docking
molecular dynamics
drug discovery
Online Access:https://www.frontiersin.org/articles/10.3389/fchem.2023.1205724/full

Internet

https://www.frontiersin.org/articles/10.3389/fchem.2023.1205724/full

Similar Items